Business
New contract worth >£1.0m
New contract worth >£1.0m.
About this update from Ixico Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7896Q\n IXICO plc\n 01 November 2021\n \n \n \n \n IXICO plc\n \n \n (\"IXICO\" or the \"Company\")\n \n \n \n \n \n Phase III demyelinating disorder contract award with largest Pharma client worth >£1.0m\n \n \n \n \n \n \n IXICO plc (AIM: IXI), the AI data analytics company delivering insights in neuroscience, announces that it has been selected by its largest pharma client to provide neuroimaging services for a new Phase III clinical trial focused on a demyelinating disorder. The study will be conducted across 100 sites in 10 countries and is worth more than £1.0m over seven years\n . \n \n \n \n \n \n \n This is the second Phase III trial in this disease area that has been awarded to the Company in the last twelve months. This reflects the Company's strategy to diversify into a broader range of neurological disorders identified as having a high unmet clinical need.\n \n \n \n \n \n Having built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders since its inception in 2004, IXICO provides advanced neuroimaging solutions and services across the entire drug development lifecycle, from Phase I through to commercialisation. The global prevalence of demyelinating diseases, conditions that result in damage to the protective covering surrounding nerve fibers in the brain, optic nerves and spinal cord such as multiple sclerosis (MS), has risen across the world over the past 10 years, increasing the need for additional drug trials and treatment options.\n \n \n \n \n Whilst this contract was already included within management's expectations for financial performance across the year, it adds to the Company's order book and further increases visibility of future revenues.\n \n \n Giulio Cerroni, CEO of IXICO, commented:\n \"\n We are delighted to be awarded the contract for this demyelinating study. Our success in being awarded two such studies during 2021 supports our decision to invest in developing new analytics solutions to a broad range of neurological disorders, including demyelinating diseases which represent an important area of research within CNS. Our mission is to support our clients in their tireless efforts to bring potential treatments to patients suffering from neurol...